JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siaens, R. H.
Right arrow Articles by Slegers, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siaens, R. H.
Right arrow Articles by Slegers, G.
Journal of Nuclear Medicine Vol. 45 No. 12 2088-2094
© 2004 by Society of Nuclear Medicine


Basic Science Investigations

Synthesis and Comparison of 99mTc-Enrofloxacin and 99mTc-Ciprofloxacin

Rien H. Siaens, Msc1, Huub J. Rennen, PhD2, Otto C. Boerman, PhD2, Rudi Dierckx, MD3 and Guido Slegers, PhD1

1 Laboratory of Radiopharmacy, Gent University, Gent, Belgium
2 Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
3 Department of Nuclear Medicine, Gent University Hospital, Gent, Belgium

The use of 99mTc-ciprofloxacin as a tracer for infection and inflammation has been examined and discussed in the literature extensively. Its alleged ability to discriminate between sterile inflammation and bacterial versus nonbacterial infections has led to an intense debate. Other labeled fluoroquinolones might offer better characteristics or may add to a better understanding of the working mechanism of 99mTc-ciprofloxacin. The rationale of this work was to determine possible differences in the use of 2 labeled quinolones—that is, 99mTc-ciprofloxacin and 99mTc-enrofloxacin—as tracers for infection and inflammation in animals. Methods: Ciprofloxacin and enrofloxacin were labeled with 99mTc and characterized. The stability of both preparations was evaluated in serum and in the presence of an excess of cysteine. In vitro binding studies were performed to determine the interaction of the labeled quinolones with bacteria and other cells. Rats with sterile and infectious intramuscular lesions were used to study the scintigraphic properties of the 2 compounds. To assess the specificity of binding to living bacteria, infectious intramuscular lesions of heat-killed Staphylococcus aureus and Candida albicans were used as controls. Imaging was performed with a {gamma}-camera at 0, 3, 5, and 22 h after injection. Results: The radiochemical purity of both radiolabeled fluoroquinolones exceeded 95% as determined by instant thin-layer chromatography. Both compounds were moderately stable in serum. Binding assays did not show any saturable binding to S. aureus, heat-killed S. aureus, as well as C. albicans. None of the tracers showed specific binding to bacteria. Scintigraphy showed uptake in the infectious lesion at 1 h after injection, which washed out during the next 4 h. Abscess-to-muscle ratios for both preparations were not significantly different for the various infectious or inflammatory lesions studied and did not exceed an average of 4.25 ± 0.62. Conclusion: The study demonstrated that 99mTc-ciprofloxacin and 99mTc-enrofloxacin do not show preferential binding to living bacteria. In vivo 99mTc-enrofloxacin has similar characteristics as 99mTc-ciprofloxacin except for differences in uptake in a few normal tissues.

Key Words: 99mTc-fluoroquinolones • inflammation, infection imaging


Related articles in JNM:

THIS MONTH IN JNM

JNM 2004 45: 8a-9a. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
T. J. Tewson
Re: Synthesis and Comparison of 99mTc-Enrofloxacin and 99mTc-Ciprofloxacin
J. Nucl. Med., June 1, 2005; 46(6): 1077 - 1077.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.